ReviewClinical microbiology reviews1996
Rotavirus vaccines: an overview.
Review in Clinical microbiology reviews, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.Vaccine · 2022Article
- Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.Journal of immunological methods · 2021Article
- Genetic characterization of G12P[6] and G12P[8] rotavirus strains collected in six African countries between 2010 and 2014.BMC infectious diseases · 2021Article
- Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.Vaccines · 2020Review
- Approaches to monitoring intussusception following rotavirus vaccination.Expert opinion on drug safety · 2019Review
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Pathogen-induced secretory diarrhea and its prevention.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
- Current status of rotavirus vaccines.World journal of pediatrics : WJP · 2015Review
- Disease caused by rotavirus infection.The open virology journal · 2014Article
- Rotavirus infection: a perspective on epidemiology, genomic diversity and vaccine strategies.Indian journal of virology : an official organ of Indian Virological Society · 2011Article
- Performance of rotavirus vaccines in developed and developing countries.Human vaccines · 2010Review
- Rotavirus vaccines: an overview.Clinical microbiology reviews · 2008Review
- Rotavirus vaccines.Indian journal of medical microbiology · 2006Review
- Memory T-cell response to rotavirus detected with a gamma interferon enzyme-linked immunospot assay.Journal of virology · 2005Article
- Cell-line-induced mutation of the rotavirus genome alters expression of an IRF3-interacting protein.The EMBO journal · 2004Article
- Defining T-cell-mediated immune responses in rotavirus-infected juvenile rhesus macaques.Journal of virology · 2004Article
- Rotavirus replication: plus-sense templates for double-stranded RNA synthesis are made in viroplasms.Journal of virology · 2004Article
- Diversity of group A human rotavirus types circulating over a 4-year period in Madrid, Spain.Journal of clinical microbiology · 2004Article
- Interferon regulatory factor 3 is a cellular partner of rotavirus NSP1.Journal of virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against rotavirus diarrhea. The goal of a rotavirus vaccine is to prevent severe illness that can lead to dehydration in infants and young children in both developed and developing countries. These studies led to the concept that a multivalent vaccine that represented each of the four epidemiologically important VP7 serotypes might be necessary to induce protection in young infants, the target population for vaccination. Human-animal rotavirus reassortants whose gene encoding VP7 was derived from their human rotavirus parent but whose remaining genes were derived from the animal rotavirus parent were developed as vaccine candidates. The greatest experience with a multivalent vaccine to date has been gained with the quadrivalent preparation containing RRV (VP7 serotype 3) and human-RRV reassortants of VP7 serotype 1, 2, and 4 specificity. Preliminary efficacy trial results in the United States have been promising, whereas a study in Peru has shown only limited protection. Human-bovine reassortant vaccines, including a candidate that contains the VP4 gene of a human rotavirus (VP4 serotype 1A), are also being studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.